Clinical Scorecard: Pediatric Gram-negative bloodstream infections: An analysis of antimicrobial resistance and mortality-related factors
At a Glance
Category
Detail
Condition
Pediatric Gram-negative bloodstream infections
Key Mechanisms
Antimicrobial resistance patterns and factors associated with mortality
Target Population
Pediatric patients aged 0–18 years
Care Setting
Tertiary care center
Key Highlights
High resistance rates observed for gentamicin (58.3%), ciprofloxacin (57.1%), imipenem (56.0%), and meropenem (48.4%)
Overall all-cause in-hospital mortality rate was 31.7%
Central venous catheter use, thrombocytopenia, total parenteral nutrition, mechanical ventilation, and meropenem resistance were associated with higher mortality
Guideline-Based Recommendations
Diagnosis
Laboratory-confirmed bloodstream infections defined by isolation of Gram-negative pathogens from blood cultures
Management
Timely initiation of appropriate antimicrobial therapy is critical
Monitoring & Follow-up
Continuous local surveillance and antimicrobial stewardship are important
Risks
Invasive procedures and broad-spectrum antibiotic exposure increase risk of antimicrobial resistance
Patient & Prescribing Data
Pediatric patients with Gram-negative bloodstream infections
Prior meropenem exposure and treatment modification after blood culture collection associated with higher mortality
Clinical Best Practices
Implement effective infection prevention and control practices
Optimize empirical treatment strategies in high-risk pediatric patients
